Antipseudomonal Versus Narrow-Spectrum Agents for the Treatment of Community-Onset Intra-abdominal Infections

被引:0
|
作者
Worden, Lacy J. [1 ]
Dumkow, Lisa E. [1 ,2 ]
VanLangen, Kali M. [1 ,3 ]
Beuschel, Thomas S. [1 ]
Jameson, Andrew P. [1 ,2 ,4 ]
机构
[1] Mercy Hlth St Marys, Dept Pharm, Grand Rapids, MI 49503 USA
[2] Mercy Hlth St Marys, Div Infect Dis, Grand Rapids, MI 49503 USA
[3] Ferris State Univ, Coll Pharm, Big Rapids, MI USA
[4] Michigan State Univ, Coll Human Med, Grand Rapids, MI USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2021年 / 8卷 / 11期
关键词
antimicrobial resistance; antipseudomonal; appendicitis; diverticulitis; intra-abdominal infections; RESISTANCE; CHILDREN;
D O I
10.1093/ofid/ofab514
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Antipseudomonal antibiotics are often used to treat community-acquired intra-abdominal infections (CA-IAIs) despite common causative pathogens being susceptible to more narrow-spectrum agents. The purpose of this study was to compare treatment-associated complications in adult patients treated for CA-IAI with antipseudomonal versus narrow-spectrum regimens. Methods. This retrospective cohort study included patients >18 years admitted for CA-IAI treated with antibiotics. The primary objective of this study was to compare 90-day treatment-associated complications between patients treated empirically with antipseudomonal versus narrow-spectrum regimens. Secondary objectives were to compare infection and treatment characteristics along with patient outcomes. Subgroup analyses were planned to compare outcomes of patients with low-risk and high-risk CA-IAIs and patients requiring surgical intervention versus medically managed. Results. A total of 350 patients were included: antipseudomonal, n = 204; narrow spectrum, n = 146. There were no differences in 90-day treatment-associated complications between groups (antipseudomonal 15.1% vs narrow spectrum 11.3%, P = .296). In addition, no differences were observed in hospital length of stay, 90-day readmission, Clostridiodes difficile, or mortality. In multivariate logistic regression, treatment with a narrow-spectrum regimen (odds ratio [OR], 0.75; 95% confidence interval, 0.39-1.45) was not independently associated with the primary outcome. No differences were observed in 90-day treatment-associated complications for (1) patients with low-risk (antipseudomonal 15% vs narrow spectrum 9.6%, P = .154) or high-risk CA-IAI (antipseudomonal 15.8% vs narrow spectrum 22.2%, P = .588) or (2) those who were surgically (antipseudomonal 8.5% vs narrow spectrum 9.2%, P = .877) or medically managed (antipseudomonal 23.1 vs narrow spectrum 14.5, P = .178). Conclusions. Treatment-associated complications were similar among patients treated with antipseudomonal and narrow-spectrum antibiotics. Antipseudomonal therapy is likely unnecessary for most patients with CA-IAI.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Feasibility of Narrow-Spectrum Antimicrobial Agents for Post-Operative Intra-Abdominal Infections After Gastrectomy
    Goto, Kentaro
    Hata, Hiroaki
    Degawa, Kanako
    Nakanishi, Yasutaka
    Obama, Kazutaka
    SURGICAL INFECTIONS, 2024, 25 (07) : 492 - 498
  • [2] Guideline-Concordant Versus Discordant Antimicrobial Therapy in Patients With Community-Onset Complicated Intra-abdominal Infections
    Huang, Lori L.
    Van Schooneveld, Trevor C.
    Huang, Robert D.
    Olsen, Keith M.
    Rupp, Mark E.
    Gross, Alan E.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2016, 37 (07): : 855 - 858
  • [3] Clinical and Economic Consequences of Failure of Initial Antibiotic Therapy for Patients with Community-Onset Complicated Intra-Abdominal Infections
    Chong, Yong Pil
    Bae, In-Gyu
    Lee, Sang-Rok
    Chung, Jin-Won
    Jun, Jae-Bum
    Choo, Eun Ju
    Moon, Soo-youn
    Lee, Mi Suk
    Jeon, Min Hyok
    Song, Eun Hee
    Lee, Eun Jung
    Park, Seong Yeon
    Kim, Yang Soo
    PLOS ONE, 2015, 10 (04):
  • [4] Treatment of complicated intra-abdominal infections: doripenem versus meropenem
    Lucasti, C.
    Jasovich, A.
    Umeh, O.
    Jiang, J.
    Kaniga, K.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S212 - S212
  • [5] Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections
    Lin, Shang-Yi
    Huang, Chung-Hao
    Ko, Wen-Chien
    Chen, Yen-Hsu
    Hsueh, Po-Ren
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (03) : 339 - 354
  • [6] AZTREONAM IN TREATMENT OF INTRA-ABDOMINAL INFECTIONS
    MALANGONI, MA
    UROLOGY, 1988, 31 (06) : 28 - 32
  • [7] Antimicrobial treatment for intra-abdominal infections
    Mazuski, John E.
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (17) : 2933 - 2945
  • [8] Antimicrobial treatment of intra-abdominal infections
    Elsakr, R
    Johnson, DA
    Younes, Z
    Oldfield, EC
    DIGESTIVE DISEASES, 1998, 16 (01) : 47 - 60
  • [9] Eravacycline for the treatment of intra-abdominal infections
    Bassetti, Matteo
    Righi, Elda
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (11) : 1575 - 1584
  • [10] Etiological Agents of Intra-abdominal Community Infections in a Polyvalent Center in Buenos Aires
    Nunez, S.
    Lacal, V.
    Cerruto, G.
    Zarate, S.
    Veron, M. T.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 126 - 126